MX2022005566A - Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg. - Google Patents

Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.

Info

Publication number
MX2022005566A
MX2022005566A MX2022005566A MX2022005566A MX2022005566A MX 2022005566 A MX2022005566 A MX 2022005566A MX 2022005566 A MX2022005566 A MX 2022005566A MX 2022005566 A MX2022005566 A MX 2022005566A MX 2022005566 A MX2022005566 A MX 2022005566A
Authority
MX
Mexico
Prior art keywords
genomanipulation
hetero
pairing
charge pair
pair mutations
Prior art date
Application number
MX2022005566A
Other languages
English (en)
Spanish (es)
Inventor
Mark Daris
Zhulun Wang
Bram Estes
Fernando Garces
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022005566A publication Critical patent/MX2022005566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022005566A 2019-11-08 2020-11-06 Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg. MX2022005566A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962933205P 2019-11-08 2019-11-08
PCT/US2020/059378 WO2021092355A1 (en) 2019-11-08 2020-11-06 Engineering charge pair mutations for pairing of hetero-igg molecules

Publications (1)

Publication Number Publication Date
MX2022005566A true MX2022005566A (es) 2022-07-19

Family

ID=73740489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005566A MX2022005566A (es) 2019-11-08 2020-11-06 Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.

Country Status (8)

Country Link
US (1) US20220389119A1 (https=)
EP (2) EP4628498A3 (https=)
JP (2) JP7677964B2 (https=)
AU (1) AU2020380379A1 (https=)
CA (1) CA3160482A1 (https=)
ES (1) ES3040852T3 (https=)
MX (1) MX2022005566A (https=)
WO (1) WO2021092355A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137454A1 (en) 2023-12-21 2025-06-26 Amgen Inc. Stabilizing homodimer mutations for two cell heterodimer production

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
IN2009DN05758A (https=) 2007-03-12 2015-07-24 Esbatech Ag
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
US20140038285A1 (en) 2011-03-11 2014-02-06 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
EP2686345B1 (en) * 2011-03-16 2018-04-25 Amgen Inc. Fc variants
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20190309092A1 (en) * 2016-07-21 2019-10-10 Development Center For Biotechnology Modified antigen-binding fab fragments and antigen-binding molecules comprising the same
DK3661954T3 (da) 2017-08-03 2022-04-19 Amgen Inc Interleukin-21-muteiner og fremgangsmåder til behandling
TW201930344A (zh) * 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法

Also Published As

Publication number Publication date
EP4055060A1 (en) 2022-09-14
EP4628498A3 (en) 2026-03-04
JP2022553813A (ja) 2022-12-26
EP4628498A2 (en) 2025-10-08
CA3160482A1 (en) 2021-05-14
ES3040852T3 (en) 2025-11-05
US20220389119A1 (en) 2022-12-08
JP2025118753A (ja) 2025-08-13
EP4055060C0 (en) 2025-07-09
JP7677964B2 (ja) 2025-05-15
WO2021092355A1 (en) 2021-05-14
AU2020380379A1 (en) 2022-05-26
EP4055060B1 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
SV2018005611A (es) Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos
CL2019002824A1 (es) Anticuerpos anti-lag3.
SV2019005807A (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
CO2019009076A2 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
CY1124619T1 (el) Αντισωματα αντι-προ/λανθανουσας μυοστατινης και χρησεις αυτων
CL2020002225A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal
MX2016005781A (es) Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t.
JOP20200300A1 (ar) أجسام مضادة لـ il-11ra
CL2017003255A1 (es) Terapias de combinación para males hematologicos con anticuerpos anti-cd38 e inhibidores de survivin.
MX2021000398A (es) Moleculas de anticuerpo que se unen a pd-l1 y cd137.
CL2020002342A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
CL2017002909A1 (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras malignidades hematologicas cd38-positiva.
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
MX393066B (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2017010667A (es) Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de unso.
UY35168A (es) Composiciones y métodos de anticuerpos de marcaje de epo
EA201591285A1 (ru) Иммунотерапия тау
AR119097A1 (es) Métodos de purificación de anticuerpos enmascarados
MX2016006595A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos de uso de las mismas.
BR112017027246A2 (pt) marcador de indução de degradação de proteína e uso do mesmo
CL2021000797A1 (es) Una ayuda para la deposición de fluidos agrícolas.
MX2022005566A (es) Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.
CL2018002689A1 (es) Metodo para purificacion de proteinas